Open AccessBiotech value chain and technologies for COVID-19 research areas for collaboration on cost quality tradeoff with tool companies
Author(s) -
Christine Huttin
Publication year - 2022
Publication title -
technology and health care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.281
H-Index - 44
eISSN - 1878-7401
pISSN - 0928-7329
DOI - 10.3233/thc-213297
Subject(s) - quality (philosophy) , quality assurance , covid-19 , business , supply chain , microbiology and biotechnology , emerging technologies , engineering management , marketing , engineering , computer science , service (business) , medicine , biology , philosophy , disease , epistemology , pathology , artificial intelligence , infectious disease (medical specialty)
BACKGROUND: Technologies for COVID-19 are in high demand, and supply chains from biotech and pharma industries face critical supply issues. OBJECTIVE: This paper discusses the case on mRNA technologies and quality assurance issues. METHODS: Interviews with managers of biotech companies were performed. These helped to prepare biotech panels at a roundtable on quality of medicine, organized by the Polish Academy of Sciences in Paris (PAN) in 2021. RESULTS: This paper analyzes the new mRNA technology and shows the importance of emerging new biotech firms, especially tool companies providing services in quality assurance. It highlights research areas and types of survey instruments with academic collaborators, to better understand the economics of mRNA technology platforms. CONCLUSIONS: A future research agenda for collaboration with academic communities is proposed on cost-quality tradeoffs and clinical quality attributes for such genomic technologies.